Limits on using the clock drawing test as a measure to evaluate patients with neurological disorders

  • Raheleh Heyrani (Creator)
  • Atiye Sarabi-Jamab (Creator)
  • Jordan Henry Grafman (Creator)
  • Nesa Asadi (Creator)
  • Sarvenaz Soltani (Creator)
  • Fatemeh Sadat Mirfazeli (Creator)
  • Mostafa Almasi-Dooghaei (Creator)
  • Seyed Vahid Shariat (Creator)
  • Amin Jahanbakhshi (Creator)
  • Tara Khoeini (Creator)
  • Mohammad Taghi Joghataei (Creator)

Dataset

Description

Abstract Background The Clock Drawing Test (CDT) is used as a quick-to-conduct test for the diagnosis of dementia and a screening tool for cognitive impairments in neurological disorders. However, the association between the pattern of CDT impairments and the location of brain lesions has been controversial. We examined whether there is an association between the CDT scores and the location of brain lesions using the two available scoring systems. Method One hundred five patients with brain lesions identified by CT scanning were recruited for this study. The Montreal Cognitive Assessment (MoCA) battery including the CDT were administered to all partcipants. To score the CDT, we used a qualitative scoring system devised by Rouleau et al. (1992). For the quantitative scoring system, we adapted the algorithm method used by Mendes-Santos et al. (2015) based on an earlier study by Sunderland et al. (1989). For analyses, a machine learning algorithm was used. Results Remarkably, 30% of the patients were not detected by the CDT. Quantitative and qualitative errors were categorized into different clusters. The classification algorithm did not differentiate the patients with traumatic brain injury ‘TBI’ from non-TBI, or the laterality of the lesion. In addition, the classification accuracy for identifying patients with specific lobe lesions was low, except for the parietal lobe with an accuracy of 63%. Conclusion The CDT is not an accurate tool for detecting focal brain lesions. While the CDT still is beneficial for use with patients suspected of having a neurodegenerative disorder, it should be cautiously used with patients with focal neurological disorders.
Date made available2023
Publisherfigshare

Cite this